2025 Volume 16 Issue 2
Creative Commons License

Consortium of Biologically Active Substances in Biotechnological Products and Their Clinical Trial


, , , ,
  1. Department of Tourism and Service Sochi State University, Sochi, Russia.
  2. Department of Management, Entrepreneurship and Engineering, Ural State University of Economics, Ekaterinburg, Russia.
  3. Scientific and Educational Center for Applied Biotechnology and Nutrition, Kemerovo State Medical University, Kemerovo.
Abstract

This article examines approaches to the comprehensive treatment and prevention of colpitis and vulvovaginal candidiasis (VVC), with a focus on the use of dietary supplements (DS). The crucial role of vaginal microflora imbalances in the development of colpitis is highlighted, justifying the use of probiotics and biocomplexes. Specific attention is given to various DS formulations, such as a Phytocomplex with black cumin oil, an Isoflavone Complex with Probiotics, a Biocomplex with fermented dietary fiber, an Intimate Mucous Membrane Care Spray, and a Biocomplex for metabolic detoxification and intestinal biocenosis correction. The composition of these DS, including plant components, probiotic strains, vitamins, microelements, and other biologically active substances, is detailed. The mechanisms of action of DS components, like the antioxidant, anti-inflammatory, and antimicrobial properties of flavonoids, are discussed, along with the role of probiotics in restoring vaginal and intestinal microflora.

Furthermore, the results of a clinical study evaluating the effectiveness of different treatment regimens using these DS in patients with chronic colpitis are presented. The study demonstrates that the proposed treatment programs, with various DS combinations, effectively alleviate symptoms and improve laboratory parameters, particularly by normalizing the microflora and eliminating pathogens. This suggests the potential of these programs for comprehensive treatment and prevention of colpitis, VVC, and other conditions associated with microbiota imbalances.


How to cite this article
Vancouver
Yurievna LE, Boisjoni T, Mikhailovich PV, Georgievna CG, Oglu AMS. Consortium of Biologically Active Substances in Biotechnological Products and Their Clinical Trial. J Biochem Technol. 2025;16(2):141-7. https://doi.org/10.51847/CNFeCcajRB
APA
Yurievna, L. E., Boisjoni, T., Mikhailovich, P. V., Georgievna, C. G., & Oglu, A. M. S. (2025). Consortium of Biologically Active Substances in Biotechnological Products and Their Clinical Trial. Journal of Biochemical Technology, 16(2), 141-147. https://doi.org/10.51847/CNFeCcajRB
Articles
Issue 4 Volume 16 - 2025